ClinicalTrials.gg
CompletedNCT04002401ZUMA-14Updated Feb 20, 2024Results posted

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

A Phase 2 interventional study of Axicabtagene Ciloleucel and Rituximab in Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing rituximab in Lymphoma, B-Cell — 8 open to participants now, 12 under way, 1 of them phase 3. Rituximab · Lymphoma, B-Cell.

Enrollment
36th of 58
27 · median 38
Started
2019
with 1 other
Phase 2
30 of 58
4 open now
Registered
42nd of 58
by date

Among the 58 studies testing rituximab in Lymphoma, B-Cell, this one is the 36th largest by enrollment, is one of 2 that started in 2019, is one of 30 in phase 2, and was the 42nd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

8 of the 58 studies testing rituximab in Lymphoma, B-Cell are open now, in 9 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing rituximab in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.

Read the detailed description

Following at least 24 months of assessments after axicabtagene ciloleucel infusion, participants will be asked to rollover to a separate long-term follow-up study (Study KT-US-982-5968). Participants will complete the remainder of the 15-year follow-up assessments in the KT-US-982-5968 study.

03

Conditions studied

  • Refractory Large B-cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed large B-cell lymphoma
  • Chemotherapy- disease, defined as one or more of the following:

    • No response to therapy (primary refractory disease)
    • No response to second or greater lines of therapy OR
    • Refractory after stem cell transplant (ASCT)
  • At least 1 measureable lesion according to the Lugano Classification (Cheson 2014).
  • Individuals must have received adequate prior therapy, including at a minimum:

    • Anti-CD20 monoclonal antibody
    • An anthracycline-containing chemotherapy regimen
  • (ECOG) performance status of 0 or 1
  • Adequate renal, hepatic, pulmonary, and cardiac function

Key Exclusion Criteria:

  • Known CD19 negative or CD20 negative tumor
  • History of Richter's transformation of Chronic Lymphocytic Leukemia (CLL)
  • Prior CAR therapy or other genetically modified T-cell therapy
  • Prior organ transplantation including prior allogeneic stem cell transplant (SCT)
  • Prior CD19 targeted therapy
  • infection or cardiopulmonary disease
  • Presence of any in-dwelling lines or drains (dedicated central venous access catheters allowed)
  • History or presence of central nervous system (CNS) lymphoma or nonmalignant CNS disorder or cerebrospinal fluid (CSF) malignant cells or
  • History of disease
  • History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last 6 months

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Axicabtagene Ciloleucel and Rituximab Combination

    Participants will receive rituximab 375 mg/m\^2, once on Day -5 along with conditioning chemotherapy (fludarabine 30 mg/m\^2 over 30 minutes and cyclophosphamide 500 mg/m\^2 over 60 minutes) once on Days -5 to -3, followed by axicabtagene ciloleucel 2 x 10\^6 anti-cluster of differentiate 19 (CD19) chimeric antigen receptor (CAR) T cells/kg once on Day 0 and additional rituximab 375 mg/m\^2 of 5 doses, once every 28 days starting from Day 21 up to Day 133.

    Biological: Axicabtagene Ciloleucel · Drug: Rituximab · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • A single infusion of CAR-transduced autologous T cells administered intravenously

    Also known as: Yescarta®

  • Administered intravenously

    Also known as: RITUXAN®

  • Administered according to package insert

  • Administered according to package insert

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate Per the International Working Group (IWG) Lugano Classification as Determined by Study Investigators

    CR rate is defined as the incidence of a CR per the IWG Lugano Classification as determined by study investigators. CR rate: percentage of participants with CR \[complete metabolic response (CMR); complete radiological response (CRR)\]. CMR: positron emission tomography (PET) 5-point scale (5-PS) scores of 1 (no uptake above background), 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass); no new lesions; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow (BM). CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in longest transverse diameter of lesion (LDi); no extralymphatic sites of disease; absent non-measured lesion (NMLs); organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% confidence interval (CI) was calculated by Clopper-Pearson method.

    Time frame: First infusion date up to maximum duration of 32.7 months

Secondary outcomes

  1. Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)

    An AE is defined as any untoward medical occurrence in a clinical trial participant that does not necessarily have a relationship with study treatment or worsening of a pre-existing medical condition. TEAEs are any AEs with onset on or after axicabtagene ciloleucel infusion or worsening of a pre-existing medical condition that occurs on or after axicabtagene ciloleucel infusion.

    Time frame: First infusion date up to maximum duration of 27 months

  2. Percentage of Participants Who Experienced Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value

    Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory parameters with only non-zero values are presented.

    Time frame: First infusion date up to maximum duration of 27 months

  3. Objective Response Rate (ORR) Per the IWG Lugano Classification as Determined by Study Investigators

    ORR: percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR); partial radiologic response (PRR)\].CMR: PET 5PS scores of 1 (no uptake above background, 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass; no new lesions; no evidence of FDG-avid disease in BM. CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in LDi;no extralymphatic sites of disease;absent NMLs;organ enlargement regress to normal;no new sites;bone marrow morphology normal. PMR: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with reduced uptake compared with baseline and residual mass; no new lesions; responding disease at interim/residual disease at end of treatment (EOT). PRR: ≥ 50% decrease in sum of the product of perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absent/normal, regressed, but no increase of NMLs; spleen regressed by \> 50% in length beyond normal; no new sites.

    Time frame: First infusion date up to maximum duration of 32.7 months

  4. Duration of Response (DOR) Per the IWG Lugano Classification as Determined by Study Investigators

    DOR is defined only for participants who experience an objective response and is the time from the first objective response to disease progression \[progressive metabolic disease (PMD); progressive radiologic disease (PRD)\] or death from any cause. Objective response is defined in outcome measure (OM) 4. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi and perpendicular diameter (PPD); increase in LDi or shortest axis perpendicular to the LDi (SDi) of 0.5 cm for lesions ≤1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. Kaplan-Meier (KM) estimate of median was reported.

    Time frame: From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (up to approximately 32.7 months)

  5. Progression-Free Survival (PFS) Per the IWG Lugano Classification as Determined by Study Investigators

    PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression (PMD; PRD) or death from any cause. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new FDG-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi and PPD; increase in LDi or SDi of 0.5 cm for lesions ≤1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. KM estimate of median was reported.

    Time frame: First infusion date up to disease progression or death regardless of cause (up to approximately 32.7 months)

  6. Overall Survival (OS)

    OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any cause. KM estimate of median was reported.

    Time frame: First infusion date up to death regardless of cause (up to approximately 32.7 months)

  7. Peak Level of Anti-CD19 CAR T Cells in Blood

    Peak was defined as the maximum number of CAR T cells in blood measured after infusion.

    Time frame: Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24

  8. Level of Anti-CD19 CAR T Cells in Blood by Visit

    Time frame: Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24

  9. Area Under the Curve of CAR T Cells From Day 0 to Day 28 (AUC0-28)

    AUC0-28 is defined as the area under curve in a plot of number of CAR T cells against scheduled visit from Day 0 to Day 28.

    Time frame: Baseline (Day 0), post-infusion on Days 7, 14, 21, and 28

  10. Time to Peak Level of Anti-CD19 CAR T Cells in Blood

    Time to peak was defined as the number of days from the date of the axicabtagene ciloleucel infusion to the date of peak level defined as the maximum number of CAR T cells in blood measured after infusion.

    Time frame: Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24

07

Results

Posted Feb 20, 2024

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestoneAxicabtagene Ciloleucel and Rituximab Combination
Started27
Completed0
Not completed27
Withdrew: Rolled over to long-term follow-up study13
Withdrew: Death10
Withdrew: Subject withdrawal of consent from further follow-up2
Withdrew: Enrolled but never treated1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryComplete Response (CR) Rate Per the International Working Group (IWG) Lugano Classification as Determined by Study Investigators

CR rate is defined as the incidence of a CR per the IWG Lugano Classification as determined by study investigators. CR rate: percentage of participants with CR \[complete metabolic response (CMR); complete radiological response (CRR)\]. CMR: positron emission tomography (PET) 5-point scale (5-PS) scores of 1 (no uptake above background), 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass); no new lesions; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow (BM). CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in longest transverse diameter of lesion (LDi); no extralymphatic sites of disease; absent non-measured lesion (NMLs); organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% confidence interval (CI) was calculated by Clopper-Pearson method.

Time frame:
First infusion date up to maximum duration of 32.7 months
Reported as:
Number · percentage of participants
Complete Response (CR) Rate Per the International Working Group (IWG) Lugano Classification as Determined by Study Investigators
percentage of participantsAxicabtagene Ciloleucel and Rituximab Combination
Complete Response (CR) Rate Per the International Working Group (IWG) Lugano Classification as Determined by Study Investigators73 (52 to 88)
SecondaryPercentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)

An AE is defined as any untoward medical occurrence in a clinical trial participant that does not necessarily have a relationship with study treatment or worsening of a pre-existing medical condition. TEAEs are any AEs with onset on or after axicabtagene ciloleucel infusion or worsening of a pre-existing medical condition that occurs on or after axicabtagene ciloleucel infusion.

Time frame:
First infusion date up to maximum duration of 27 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)
percentage of participantsAxicabtagene Ciloleucel and Rituximab Combination
Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)100
SecondaryPercentage of Participants Who Experienced Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value

Grading categories were determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory parameters with only non-zero values are presented.

Time frame:
First infusion date up to maximum duration of 27 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Laboratory Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Value
percentage of participantsAxicabtagene Ciloleucel and Rituximab Combination
Alanine Aminotransferase12
Aspartate Aminotransferase12
Bilirubin8
Calcium8
Direct Bilirubin15
Glucose19
Magnesium8
Urate8
SecondaryObjective Response Rate (ORR) Per the IWG Lugano Classification as Determined by Study Investigators

ORR: percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR); partial radiologic response (PRR)\].CMR: PET 5PS scores of 1 (no uptake above background, 2 (uptake ≤ mediastinum), 3 (uptake \> mediastinum but ≤ liver) with/without a residual mass; no new lesions; no evidence of FDG-avid disease in BM. CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in LDi;no extralymphatic sites of disease;absent NMLs;organ enlargement regress to normal;no new sites;bone marrow morphology normal. PMR: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with reduced uptake compared with baseline and residual mass; no new lesions; responding disease at interim/residual disease at end of treatment (EOT). PRR: ≥ 50% decrease in sum of the product of perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absent/normal, regressed, but no increase of NMLs; spleen regressed by \> 50% in length beyond normal; no new sites.

Time frame:
First infusion date up to maximum duration of 32.7 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per the IWG Lugano Classification as Determined by Study Investigators
percentage of participantsAxicabtagene Ciloleucel and Rituximab Combination
Objective Response Rate (ORR) Per the IWG Lugano Classification as Determined by Study Investigators88 (70 to 98)
SecondaryDuration of Response (DOR) Per the IWG Lugano Classification as Determined by Study Investigators

DOR is defined only for participants who experience an objective response and is the time from the first objective response to disease progression \[progressive metabolic disease (PMD); progressive radiologic disease (PRD)\] or death from any cause. Objective response is defined in outcome measure (OM) 4. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new fluorodeoxyglucose (FDG)-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi and perpendicular diameter (PPD); increase in LDi or shortest axis perpendicular to the LDi (SDi) of 0.5 cm for lesions ≤1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. Kaplan-Meier (KM) estimate of median was reported.

Time frame:
From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (up to approximately 32.7 months)
Reported as:
Median · months
Duration of Response (DOR) Per the IWG Lugano Classification as Determined by Study Investigators
monthsAxicabtagene Ciloleucel and Rituximab Combination
Duration of Response (DOR) Per the IWG Lugano Classification as Determined by Study Investigators26.0 (2.6 to NA)
SecondaryProgression-Free Survival (PFS) Per the IWG Lugano Classification as Determined by Study Investigators

PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression (PMD; PRD) or death from any cause. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new FDG-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi and PPD; increase in LDi or SDi of 0.5 cm for lesions ≤1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. KM estimate of median was reported.

Time frame:
First infusion date up to disease progression or death regardless of cause (up to approximately 32.7 months)
Reported as:
Median · months
Progression-Free Survival (PFS) Per the IWG Lugano Classification as Determined by Study Investigators
monthsAxicabtagene Ciloleucel and Rituximab Combination
Progression-Free Survival (PFS) Per the IWG Lugano Classification as Determined by Study Investigators23.6 (3.4 to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any cause. KM estimate of median was reported.

Time frame:
First infusion date up to death regardless of cause (up to approximately 32.7 months)
Reported as:
Median · months
Overall Survival (OS)
monthsAxicabtagene Ciloleucel and Rituximab Combination
Overall Survival (OS)NA (25.8 to NA)
SecondaryPeak Level of Anti-CD19 CAR T Cells in Blood

Peak was defined as the maximum number of CAR T cells in blood measured after infusion.

Time frame:
Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24
Reported as:
Median · cells per microliter (cells/µL)
Peak Level of Anti-CD19 CAR T Cells in Blood
cells per microliter (cells/µL)Axicabtagene Ciloleucel and Rituximab Combination
Peak Level of Anti-CD19 CAR T Cells in Blood40.33 (1.15 to 304.36)
SecondaryLevel of Anti-CD19 CAR T Cells in Blood by Visit
Time frame:
Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24
Reported as:
Median · cells/µL
Level of Anti-CD19 CAR T Cells in Blood by Visit
cells/µLAxicabtagene Ciloleucel and Rituximab Combination
Baseline (Day 0)0.00 (0.00 to 0.00)
Day 7 Post-infusion18.11 (1.15 to 304.36)
Day 14 Post-infusion12.74 (0.05 to 172.54)
Day 21 Post-infusion4.66 (0.02 to 43.26)
Day 28 Post-infusion1.66 (0.03 to 17.14)
Day 49 Post-infusion0.99 (0.01 to 26.49)
Day 105 Post-infusion0.32 (0.00 to 1.23)
Day 180 Post-infusion0.09 (0.00 to 1.34)
Month 9 Post-infusion0.06 (0.00 to 1.01)
Month 12 Post-infusion0.0054 (0.00 to 0.91)
Month 15 Post-infusion0.0027 (0.00 to 0.47)
Month 18 Post-infusion0.00 (0.00 to 0.36)
Month 24 Post-infusion0.00 (0.00 to 0.00)
SecondaryArea Under the Curve of CAR T Cells From Day 0 to Day 28 (AUC0-28)

AUC0-28 is defined as the area under curve in a plot of number of CAR T cells against scheduled visit from Day 0 to Day 28.

Time frame:
Baseline (Day 0), post-infusion on Days 7, 14, 21, and 28
Reported as:
Median · cells/μL*days
Area Under the Curve of CAR T Cells From Day 0 to Day 28 (AUC0-28)
cells/μL*daysAxicabtagene Ciloleucel and Rituximab Combination
Area Under the Curve of CAR T Cells From Day 0 to Day 28 (AUC0-28)376.83 (14.93 to 3430.50)
SecondaryTime to Peak Level of Anti-CD19 CAR T Cells in Blood

Time to peak was defined as the number of days from the date of the axicabtagene ciloleucel infusion to the date of peak level defined as the maximum number of CAR T cells in blood measured after infusion.

Time frame:
Baseline (Day 0), post-infusion on Days 7, 14, 21, 28, 49, 105, 180, Months 9, 12, 15, 18, and 24
Reported as:
Median · days
Time to Peak Level of Anti-CD19 CAR T Cells in Blood
daysAxicabtagene Ciloleucel and Rituximab Combination
Time to Peak Level of Anti-CD19 CAR T Cells in Blood8 (8 to 21)

Adverse events

Collected over All-cause mortality: Enrollment up to last follow up visit (maximum duration of 37.9 months); Adverse events: First infusion date up to maximum duration of 27 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axicabtagene Ciloleucel and Rituximab Combination11/27 (40.7%)14/26 (53.8%)26/26 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventAxicabtagene Ciloleucel and Rituximab Combination
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/26
PyrexiaGeneral disorders3/26
AnaemiaBlood and lymphatic system disorders2/26
PneumoniaInfections and infestations2/26
SepsisInfections and infestations2/26
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/26
Confusional statePsychiatric disorders2/26
Febrile neutropeniaBlood and lymphatic system disorders1/26
ChillsGeneral disorders1/26
Covid-19 pneumoniaInfections and infestations1/26
Most frequent other events
Showing 10 of 60
Most frequent other events
EventAxicabtagene Ciloleucel and Rituximab Combination
PyrexiaGeneral disorders23/26
Neutrophil count decreasedInvestigations17/26
NauseaGastrointestinal disorders16/26
HypotensionVascular disorders15/26
AnaemiaBlood and lymphatic system disorders13/26
HeadacheNervous system disorders12/26
FatigueGeneral disorders10/26
Decreased appetiteMetabolism and nutrition disorders10/26
Confusional statePsychiatric disorders9/26
TachycardiaCardiac disorders8/26

Baseline characteristics

Safety analysis set included all participants treated with any dose of axicabtagene ciloleucel.

Age, Categorical
Age, Categorical(Participants)Axicabtagene Ciloleucel and Rituximab Combination
<=18 years0
Between 18 and 65 years14
>=65 years12
Age, Continuous
Age, Continuous(years)Axicabtagene Ciloleucel and Rituximab Combination
Mean60 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Axicabtagene Ciloleucel and Rituximab Combination
Female12
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Axicabtagene Ciloleucel and Rituximab Combination
Hispanic or Latino4
Not Hispanic or Latino21
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Axicabtagene Ciloleucel and Rituximab Combination
Race — White19
Race — Other or More Than One Race4
Race — Asian3
Region of Enrollment
Region of Enrollment(Participants)Axicabtagene Ciloleucel and Rituximab Combination
United States26
08

Study locations

14 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • City of Hope National Medical Center
    Duarte, California 91010-3012, United States
  • Stanford Cancer Institute
    Palo Alto, California 94305, United States
  • UCLA Hematology/Oncology
    Santa Monica, California 90404, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Columbia University Medical Center, New York Presbyterian Hospital
    New York, New York 10032, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • St. David's South Austin Medical Center
    Austin, Texas 78704, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jan 2023, 38 months.

Results were first posted in Feb 2024, 1 year after primary completion.

Of 121 phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 73. This study's 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2019
First posted
Jun 28, 2019
StartActual
Nov 5, 2019
Primary completionActual
Jan 30, 2023
CompletionActual
Jan 30, 2023
Results first posted
Feb 20, 2024
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04002401
Responsible party
Sponsor
First posted
Jun 28, 2019
Start date
Nov 5, 2019
Primary completion
Jan 30, 2023
Completion
Jan 30, 2023
Results posted
Feb 20, 2024
Last update
Feb 20, 2024

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Axicabtagene ciloleucel · Rituximab

Start the discussion